- Pivotal acquisition in Envision Pharma Group’s tech-enabled offerings provides clients with access to advanced AI to accelerate decision-making which optimises their products’ path to market and ultimately support the delivery of enhanced patient outcomes.
08 February 2023
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Envision Pharma Group, regarding its acquisition of OKRA.ai.
Envision Pharma Group (Envision), a leading global technology-enabled commercialisation, integrated medical capabilities and solutions, and data analytics partner to the life science industry, announced it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with present brains across commercialisation, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.
OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and drive action to clients in the life sciences industry.
“We are delighted to welcome OKRA.ai into the Envision Pharma Group family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence solutions and expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly support patients in their journey to health and wellness.”
Dr. Loubna Bouarfa, founder of OKRA.ai will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining force with Envision and see enormous opportunities for the growth of our combined expertise and solutions for clients in the life science industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life science industry. Our success will not only bring commercial benefit to clients but lead to improved patient outcomes across the globe.”
Based in the UK and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1,400+ employees across four continents.